Log in to save to my catalogue

Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyo...

Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyo...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_51f572bcdff644bcab3c3cc538fd0d47

Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Inhibition of mTOR is the standard of care for lymphangioleiomyomatosis (LAM). However, this therapy has variable tolerability and some patients show progressive decline of lung function despite treatment. LAM diagnosis and monitoring can also be challenging due to the heterogeneity of symptoms and insufficiency of non‐invasive tests. Here, we prop...

Alternative Titles

Full title

Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_51f572bcdff644bcab3c3cc538fd0d47

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_51f572bcdff644bcab3c3cc538fd0d47

Other Identifiers

ISSN

1757-4676

E-ISSN

1757-4684

DOI

10.15252/emmm.202113929

How to access this item